TY  - CONF
AU  - Stark, Melina
AU  - Kuhn, Elizabeth
AU  - Wagner, Michael
AU  - Boecker, Henning
AU  - Brosseron, Frederic
AU  - Buerger, Katharina
AU  - Daamen, Marcel
AU  - Laske, Christoph
AU  - Perneczky, Robert
AU  - Peters, Oliver
AU  - Priller, Josef
AU  - Schmid, Matthias
AU  - Schneider, Anja
AU  - Spottke, Annika
AU  - Teipel, Stefan J
AU  - Wiltfang, Jens
AU  - Düzel, Emrah
AU  - Jessen, Frank
AU  - Kleineidam, Luca
TI  - Subjective Cognitive Decline and Minor Neuropsychological Deficits: Importance for Risk Stratification and Trial Recruitment in Early Alzheimer´s Disease
JO  - Alzheimer's and dementia
VL  - 21
IS  - Suppl 3
SN  - 1552-5260
M1  - DZNE-2025-01475
SP  - e102815
PY  - 2025
AB  - The recruitment of participants with a high risk of decline is crucial for the success of clinical trials in the earliest phases of Alzheimer´s Disease (AD), where treatment benefits could be the largest. Subjective cognitive decline (SCD) and minor neuropsychological deficits (MNPD) are associated with an increased risk of cognitive decline, making them promising predictors for this risk stratification. However, the prognostic value of their interplay is understudied.We pooled and analyzed data from cognitively unimpaired participants from the Alzheimer´s Disease Neuroimaging Initiative (N = 599), DZNE Longitudinal Cognitive Impairment and Dementia study (N = 618), and National Alzheimer's Coordinating Center (N = 11,975). SCD was measured using questionnaires or anamnestic data. MNPD was defined as a median neuropsychological test performance of z≤-0.5. We assessed the association of MNPD and SCD with the conversion to mild cognitive impairment (MCI) and dementia (cox regression) and baseline amyloid and tau positivity - measured by PET/CSF (logistic regression). We adjusted these models for the study cohorts and demographic covariates. Using power analyses, we calculated the sample sizes necessary to detect a 30
T2  - Alzheimer’s Association International Conference
CY  - 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2  - 27 Jul 2025 - 31 Jul 2025
M2  - Toronto, Canada
KW  - Humans
KW  - Male
KW  - Female
KW  - Aged
KW  - Cognitive Dysfunction: diagnosis
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Cognitive Dysfunction: cerebrospinal fluid
KW  - Cognitive Dysfunction: psychology
KW  - Neuropsychological Tests
KW  - Alzheimer Disease: diagnostic imaging
KW  - Alzheimer Disease: diagnosis
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: psychology
KW  - tau Proteins: cerebrospinal fluid
KW  - Disease Progression
KW  - Longitudinal Studies
KW  - Aged, 80 and over
KW  - Positron-Emission Tomography
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Biomarkers: cerebrospinal fluid
KW  - tau Proteins (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
C6  - pmid:41447391
C2  - pmc:PMC12740029
DO  - DOI:10.1002/alz70857_102815
UR  - https://pub.dzne.de/record/283068
ER  -